<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>) when added to <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects (1:1:1) to once-daily liraglutide (1.2 or 1.8 mg) or liraglutide placebo in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> (1 g twice daily) and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (4 mg twice daily) </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects had type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, A1C 7-11% (previous oral antidiabetes drug [OAD] monotherapy &gt;or=3 months) or 7-10% (previous OAD combination therapy &gt;or=3 months), and BMI &lt;or=45 kg/m(2) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Mean A1C values decreased significantly more in the liraglutide groups versus placebo (mean +/- SE -1.5 +/- 0.1% for both 1.2 and 1.8 mg liraglutide and -0.5 +/- 0.1% for placebo) </plain></SENT>
<SENT sid="4" pm="."><plain>Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> decreased by 40, 44, and 8 mg/dl for 1.2 and 1.8 mg and placebo, respectively, and 90-min postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> decreased by 47, 49, and 14 mg/dl, respectively (P &lt; 0.001 for <z:hpo ids='HP_0000001'>all</z:hpo> liraglutide groups vs. placebo) </plain></SENT>
<SENT sid="5" pm="."><plain>Dose-dependent <z:hpo ids='HP_0001824'>weight loss</z:hpo> occurred with 1.2 and 1.8 mg liraglutide (1.0 +/- 0.3 and 2.0 +/- 0.3 kg, respectively) (P &lt; 0.0001) compared with <z:mp ids='MP_0005456'>weight gain</z:mp> with placebo (0.6 +/- 0.3 kg) </plain></SENT>
<SENT sid="6" pm="."><plain>Systolic blood pressure decreased by 6.7, 5.6, and 1.1 mmHg with 1.2 and 1.8 mg liraglutide and placebo, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Significant increases in C-<z:chebi fb="7" ids="16670">peptide</z:chebi> and homeostasis model assessment of beta-cell function and significant decreases in the proinsulin-to-insulin ratio occurred with liraglutide versus placebo </plain></SENT>
<SENT sid="8" pm="."><plain>Minor <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> occurred more frequently with liraglutide, but there was no major <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Gastrointestinal adverse events were more common with liraglutide, but most occurred early and were transient </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Liraglutide combined with <z:chebi fb="0" ids="6801">metformin</z:chebi> and a thiazolidinedione is a well-tolerated combination therapy for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, providing significant improvements in glycemic control </plain></SENT>
</text></document>